PT  - JOURNAL ARTICLE
AU  - Joana Marmy
AU  - Jens Diedrich
AU  - Thomas Dieterle
AU  - Jörg Leuppi
TI  - COPD GOLD 2017 guidelines adherence in Swiss pulmologists and general practitioners
AID  - 10.1183/13993003.congress-2018.PA911
DP  - 2018 Sep 15
TA  - European Respiratory Journal
PG  - PA911
VI  - 52
IP  - suppl 62
4099  - http://erj.ersjournals.com/content/52/suppl_62/PA911.short
4100  - http://erj.ersjournals.com/content/52/suppl_62/PA911.full
SO  - Eur Respir J2018 Sep 15; 52
AB  - Background: A major revision of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines on chronic obstructive pulmonary disease (COPD) was published 2017.Objective: Explore loyalty to GOLD 2017 amongst pulmologists and general practitioners.Methods: A questionnaire-based survey was approved by ethics committee. 92 physicians from Switzerland reported demographics, dyspnoea status and current therapy of COPD patients. Patients were sorted into the GOLD 2017 treatment gird A to D. A correct therapy for GOLD A was defined as a short-acting beta-agonist (SABA), or short-acting muscarinic-antagonist (SAMA). For GOLD B and C, either a long-acting beta-agonist (LABA), long-acting muscarinic-antagonist (LAMA), or LAMA/LABA combination was judged as acceptable. The use of inhaled corticosteroid (ICS) was valued incorrect for GOLD groups A to C. In GOLD D a correct therapy was at least the use of a LAMA/LABA combination.Results: In total 511 Patients, 288 (56.4%) men and 223 (43.6%) women, were enrolled. 140 (27.4%) patients were grouped GOLD A, 184 (36.0 %) GOLD B, 61 (11.9%) GOLD C and 118 (23.1%) GOLD D. In GOLD A, 122 (87.1%) patients were over-treated with a LABA, LAMA, ICS or combination therapy. 96 (52.2%) GOLD B and 30 (49.2%) GOLD C patients were treated correct. 68 (37.0%) GOLD B and 29 (47.5%) GOLD C were over-treated. GOLD D grouped patients were treated best, as 93 (78.8%) patients receiving a therapy in accordance with the guidelines. Nevertheless, 18 (15.2%) GOLD D patients were undertreated.Conclusion: Half of the COPD patients are still over-treated by ICS. Further educational efforts by the society are needed to get patients on adequate treatment.FootnotesCite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA911.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).